| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,243.0 | 1,126.1 |
| Profit before tax | -458.9 | 9.0 |
| Net income | -483.4 | 251.4 |
| EPS (diluted, $ a share) | $-7.48 | $4.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.4% |
|---|---|
| Operating margin | -33.3% |
10-Q filed with the SEC, NASDAQ: JAZZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Jazz Pharmaceuticals plc: key numbers
- Share price
- $239.77Close, Nov 16
- Market cap
- $15.4B
- Shares outstanding
- 64.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Jazz Pharmaceuticals plc
All →Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $16.2M of Stock
Bruce C. Cozadd sold 68,808 shares of Jazz Pharmaceuticals plc at $234.91 to $237.39 a share (average $235.95) in 4 transactions, worth $16.2M in total on Nov 6, 2026. Shares held after the trade: 357,567 (-1.6%).
- Value
- $16.2M
- Shares
- 68,808
- Average price
- $235.95
- Holding change
- -1.6%
- Trade date
- Nov 6, 2026
Jazz Pharmaceuticals SVP, CAO Patricia Carr Sells $327K of Stock
Patricia Carr, SVP, CAO, sold 1,413 shares of Jazz Pharmaceuticals plc at $231.27 to $231.37 a share (average $231.36) in 2 transactions, worth $327K in total on Nov 4, 2026. Shares held after the trade: 6,512 (-2.4%).
- Value
- $327K
- Shares
- 1,413
- Average price
- $231.36
- Role
- SVP, CAO
- Holding change
- -2.4%
- Trade date
- Nov 4, 2026
Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $225K of Stock
Renee D. Gala, President & CEO, sold 1,000 shares of Jazz Pharmaceuticals plc at $225.37 a share, worth $225K in total on Nov 3, 2026. Shares held after the trade: 140,394 (-0.7%).
- Value
- $225K
- Shares
- 1,000
- Price
- $225.37
- Role
- President & CEO
- Holding change
- -0.7%
- Trade date
- Nov 3, 2026
Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.3M of Stock
Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $215.84 a share, worth $1.3M in total on Nov 2, 2026. Shares held after the trade: 339,875 (-1.7%).
- Value
- $1.3M
- Shares
- 6,000
- Price
- $215.84
- Holding change
- -1.7%
- Trade date
- Nov 2, 2026
Jazz Pharmaceuticals Financial Results
Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and the launch of Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion and highlighted the closing of its acquisition of Actio Biosciences.
“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance. At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”
Renee Gala, president and chief executive officer of Jazz Pharmaceuticals
Jazz Pharmaceuticals Business Update
Jazz Pharmaceuticals provided a preliminary update on its Q3 2026 financial results, estimating a $755 million pre-tax charge for acquired in-process research and development (IPR&D) related to its acquisition of Actio Biosciences. This non-deductible charge is expected to have an unfavorable impact of approximately $11.00 on both GAAP and non-GAAP adjusted earnings per share for the quarter.
- Counterparty
- Actio Biosciences, Inc.